<DOC>
	<DOC>NCT00459719</DOC>
	<brief_summary>The patients about to undergo liver transplantation will be randomized to one of the following two group: Group FK506MR: FK506MR/steroid; Group Prograf® : Prograf® /steroid The treatment period is 3 months(12 weeks</brief_summary>
	<brief_title>A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Written informed consent with the date of the patient must be obtained. Patient between 1870 years of age receiving the primary liver. Female patients must have a negative pregnancy test prior to the enrolment. Female patients of child bearing potential must agree to practice effective birth control during the study Liver retransplantation patients or received an organ transplantation other than a liver. Livingrelated liver transplantation patient. Patient has received an AB0 incompatible donor liver. Patient who needs antibody induction therapy. Patient with sever infection requiring treatment. Patient has any history of severe cardiovascular, respiratory disease; or history of malignancy, liver cancer not included.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Prednisolone</keyword>
</DOC>